Endo (ENDP) Ratings Placed on Review for Downgrade by Moody's Following Par Pharma Announcement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Raises Price Target on Endo Int'l (ENDP) Leading up to Par Pharma Acquisition
May 19, 2015 7:42 AM EDTPiper Jaffray reiterates an Overweight rating on Endo International plc (NASDAQ: ENDP), and raised the price target to $117.00 (from $110.00), leading up to the Par Pharmaceuticals acquisition. Endo plans on Acquiring Par for $8B.
Piper Jaffray analyst David Amsellem commented on Endo, saying, "Endo is... More
